These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7923559)

  • 41. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
    Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
    Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo.
    Miller TR; Bianchi BR; Witte DG; Lin CW
    Regul Pept; 1993 Jan; 43(1-2):107-12. PubMed ID: 8426907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
    Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
    Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of the CCK receptor antagonist MK-329 on food intake in broiler chickens.
    Covasa M; Forbes JM
    Pharmacol Biochem Behav; 1994 Jun; 48(2):479-86. PubMed ID: 8090818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of non-peptidal CCK receptor antagonist (L-364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs.
    Konturek SJ; Tasler J; Konturek JW; Cieszkowski M; Szewczyk K; Hładij M; Anderson PS
    Gut; 1989 Jan; 30(1):110-7. PubMed ID: 2920915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats.
    Reidelberger RD
    Am J Physiol; 1992 Dec; 263(6 Pt 2):R1354-8. PubMed ID: 1481948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term blockade of cholecystokinin (CCK): effects of L 364,718 (a CCK receptor antagonist) on pancreatic enzyme storage and secretion.
    Rodriguez AI; Manso MA; Garcia-Montero AC; Orfao A; de Dios I
    Pancreas; 1997 Oct; 15(3):314-22. PubMed ID: 9336798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line.
    Lignon MF; Bernad N; Martinez J
    Eur J Pharmacol; 1993 May; 245(3):241-6. PubMed ID: 8335062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of cisplatin resistance in human malignant melanoma cells.
    McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
    Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism.
    Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
    Dourish CT; Rycroft W; Iversen SD
    Science; 1989 Sep; 245(4925):1509-11. PubMed ID: 2781294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
    Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Properties of receptors for gastrin and CCK on gastric smooth muscle cells.
    Menozzi D; Gardner JD; Jensen RT; Maton PN
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of bombesin-induced pancreatic secretion in unanesthetized rats.
    Liehr RM; Reidelberger RD; Varga G; Solomon TE
    Peptides; 1993; 14(4):717-23. PubMed ID: 8234015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9- to 12-day-old rat pups.
    Smith GP; Tyrka A; Gibbs J
    Pharmacol Biochem Behav; 1991 Jan; 38(1):207-10. PubMed ID: 2017446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SCH 23390-induced hypophagia is blocked by the selective CCK-A receptor antagonist devazepide, but not by the CCK-B/gastrin receptor antagonist L-365,260.
    Cooper SJ; Barber DJ
    Brain Res Bull; 1990 Apr; 24(4):631-3. PubMed ID: 2141538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
    Vasar E; Stephenson JD; Meldrum BS
    Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity.
    Akaike A; Tamura Y; Sato Y; Ozaki K; Matsuoka R; Miura S; Yoshinaga T
    Brain Res; 1991 Aug; 557(1-2):303-7. PubMed ID: 1684128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.